JAMA Network
About The Study: Approximately 1 in 30 trials and more than 74,000 trial participants were affected by grant funding disruptions. Affected trials disproportionately studied infectious diseases, prevention, and behavioral interventions, and were based in the Northeastern U.S. or in other countries. Because trials require sustained financial support to ensure operations and participant safety, unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
